Siamab Therapeutics

Siamab is developing therapeutic antibodies targeting glycan alterations present in the majority of solid tumors — including colon, lung, ovarian, breast, prostate, and pancreatic cancer. Cancer cells mutate the glycans present on the cell surface to enable tissue invasion and metastases. Targeting glycans with antibodies offers the potential to provide patients with significant benefits in reducing tumor burden by both killing tumor cells and blocking metastatic behavior.